| Generic name | Anagrelide hydrochloride |
| Pronunciation | an-AH-gre-lide HYE-droe-KLOR-ide |
| Brand name(s), other common name(s) | Agrylin® |
| Drug type | Platelet-reducing agent |
| How the drug is given | By mouth |
Indications and Usage
Anagrelide hydrochloride is FDA approved for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to improve associated symptoms including thrombo-hemorrhagic events (a process that involves either a blood clot or bleeding, such as a heart attack or stroke).
Side effects needing medical attention
Lack of strength; headache; fever; malaise; pain; abdominal pain; palpitations; faster than normal heartbeat; anorexia; diarrhea; indigestion; flatulence; nausea; vomiting; edema; dizziness; paresthesia (a skin sensation, such as burning, prickling, itching, or tingling, with no apparent physical cause); cough; shortness of breath; sore throat; itchy skin; rash.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.